Literature DB >> 16261285

Different clinical features in patients with limited and diffuse cutaneous systemic sclerosis.

Predrag Ostojić1, Nemanja Damjanov.   

Abstract

This study aims to analyze differences among established disease damage indicators in patients with limited cutaneous systemic sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSc). Fifty patients with lcSSc and 55 patients with dcSSc were included in this study. Difference in mean disease duration between the two subgroups of patients was not statistically significant (z=-0.88, p=0.38). Patients with lcSSc and dcSSc were compared, and differences in vascular, esophageal, lung, heart, renal, and musculoskeletal involvement were statistically assessed using chi (2), Mann-Whitney, and Kruskal-Wallis tests. Using the technique of nailfold capillaroscopy, we found normal capillaries or nonspecific capillary change in 10.0% of the patients with lcSSc and only in 3.6% of the patients with dcSSc. Dilated capillaries without loss of capillaries were found in 42% of the patients with lcSSc and in 10.9% of the patients with dcSSc (p=0.05). However, severe capillary damage (loss of capillaries) was noticed more frequently in patients with dcSSc (dcSSc/lcSSc: 85.5%/48.0%, p=0.002). Pitting scars or digital ulcers were found in 46.0% of the patients with lcSSc and in 67.3% of the patients with dcSSc (p=0.04). We did not notice a significant difference in frequency of fingertip osteolysis and telangiectasia. Esophageal hypomotility was found in 64% of the patients with lcSSc and in 85.5% of the patients with dcSSc (p<0.01). We found interstitial lung fibrosis more frequently in patients with dcSSc (lcSSc/dcSSc: 16.0%/72.7%, p<0.001). Reduced forced vital capacity (FVC) was found in 6.0% of the of patients with lcSSc and in 41.8% of the patients with dcSSc (p<0.001). A decreased value of the transfer factor for carbon monoxide (DLCO) was also observed more frequently in patients with dcSSc. Heart involvement was found in 29.1% of the patients with dcSSc and less frequently (p<0.001) in patients with lcSSc (8%). Similarly, we found renal involvement more frequently in patients with dcSSc (lcSSc/dcSSc: 2.0%/16.3%). Tendon friction rubs were noticed in 23.6% of the patients with dcSSc and only in 6% of the patients with lcSSc (p<0.01). Joint contractures were observed in 70.9% of the patients with dcSSc and in 26.0% of the patients with lcSSc (p<0.001). Muscle weakness was noticed more frequently in patients with dcSSc (lcSSc/dcSSc: 22.0%/40.0%, p<0.05). Arthralgia was found more frequently in patients with dcSSc, but arthritis became apparent, without significant difference in frequency, in 16% of the patients with lcSSc and in 16.4% of the patients with dcSSc. Loss of capillaries (detected by nailfold capillaroscopy), digital ulcers, interstitial lung fibrosis, decreased FVC and DLCO, esophageal hypomotility, musculoskeletal impairment, and heart and renal involvement are more common in patients with dcSSc. Fingertip osteolysis, telangiectasia, and arthritis are equally frequent in both forms of the disease.

Entities:  

Mesh:

Year:  2006        PMID: 16261285     DOI: 10.1007/s10067-005-0041-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  15 in total

1.  European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres.

Authors:  A Della Rossa; G Valentini; S Bombardieri; W Bencivelli; A J Silman; S D'Angelo; M M Cerinic; J F Belch; C M Black; R Becvar; P Bruhlman; F Cozzi; L Czirják; A A Drosos; B Dziankowska; C Ferri; A Gabrielli; R Giacomelli; G Hayem; M Inanc; N J McHugh; H Nielsen; R Scorza; E Tirri; F H van den Hoogen; P G Vlachoyiannopoulos
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

Review 2.  Evaluation and management of pulmonary hypertension in systemic sclerosis.

Authors:  Ioana R Preston; Nicholas S Hill
Journal:  Curr Opin Rheumatol       Date:  2003-11       Impact factor: 5.006

3.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

Authors:  E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

4.  Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis.

Authors:  S Jacobsen; P Halberg; S Ullman; W J Van Venrooij; M Høier-Madsen; A Wiik; J Petersen
Journal:  Br J Rheumatol       Date:  1998-01

5.  A modified scleroderma skin scoring method.

Authors:  M B Kahaleh; G L Sultany; E A Smith; J E Huffstutter; C B Loadholt; E C LeRoy
Journal:  Clin Exp Rheumatol       Date:  1986 Oct-Dec       Impact factor: 4.473

6.  Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis.

Authors:  V D Steen; D L Powell; T A Medsger
Journal:  Arthritis Rheum       Date:  1988-02

7.  Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis?

Authors:  E Diot; B Giraudeau; P Diot; D Degenne; L Ritz; J L Guilmot; E Lemarié
Journal:  Chest       Date:  1999-09       Impact factor: 9.410

8.  Relationship between cutaneous and pulmonary involvement in systemic sclerosis.

Authors:  S Morelli; C Barbieri; A Sgreccia; L Ferrante; V Pittoni; F Conti; G Gualdi; E Polettini; O A Carlesimo; S Calvieri
Journal:  J Rheumatol       Date:  1997-01       Impact factor: 4.666

9.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

Review 10.  Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies.

Authors:  Michelle L Harris; Antony Rosen
Journal:  Curr Opin Rheumatol       Date:  2003-11       Impact factor: 5.006

View more
  26 in total

Review 1.  Lung involvement in systemic sclerosis.

Authors:  Paul M Hassoun
Journal:  Presse Med       Date:  2010-12-30       Impact factor: 1.228

Review 2.  The promising role of lung ultrasound in systemic sclerosis.

Authors:  A Delle Sedie; L Carli; E Cioffi; S Bombardieri; L Riente
Journal:  Clin Rheumatol       Date:  2012-07-29       Impact factor: 2.980

3.  Organ involvement in Argentinian systemic sclerosis patients with "late" pattern as compared to patients with "early/active" pattern by nailfold capillaroscopy.

Authors:  Lucila Marino Claverie; Elizabeth Knobel; Lorena Takashima; Lorena Techera; Marina Oliver; Paula Gonzalez; Félix E Romanini; María L Fonseca; Marta N Mamani
Journal:  Clin Rheumatol       Date:  2013-02-16       Impact factor: 2.980

Review 4.  Interstitial lung disease in systemic sclerosis.

Authors:  Predrag Ostojic; Marco Matucci Cerinic; Richard Silver; Kristin Highland; Nemanja Damjanov
Journal:  Lung       Date:  2007 Jul-Aug       Impact factor: 2.584

Review 5.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01

6.  Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study.

Authors:  Karen Au; Maureen D Mayes; Paul Maranian; Philip J Clements; Dinesh Khanna; Virginia D Steen; Donald Tashkin; Michael D Roth; Robert Elashoff; Daniel E Furst
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-12       Impact factor: 4.794

7.  Scleroderma lung disease.

Authors:  Jérôme Le Pavec; David Launay; Stephen C Mathai; Paul M Hassoun; Marc Humbert
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

Review 8.  The role of capillaroscopy in differentiation of primary and secondary Raynaud's phenomenon in rheumatic diseases: a review of the literature and two case reports.

Authors:  Sevdalina Nikolova Lambova; Ulf Müller-Ladner
Journal:  Rheumatol Int       Date:  2009-06-23       Impact factor: 2.631

9.  Rapidly progressive fatal interstitial lung disease in a patient with systemic sclerosis.

Authors:  Kristine Phillips; Cathryn Byrne-Dugan; Eric Batterson; James R Seibold
Journal:  Nat Rev Rheumatol       Date:  2009-04       Impact factor: 20.543

Review 10.  Gastrointestinal manifestations of systemic sclerosis.

Authors:  Robyn Domsic; Kenneth Fasanella; Klaus Bielefeldt
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.